Drug Trial Radar · NCT07232004
A Study to Evaluate How the Study Drug Moves Through the Body, Adverse Events, and How the Body Tolerates ABBV-547 Injections
Last checked: Nov 19, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
142
Planned (sponsor's estimate)
Start
Nov 24, 2025
Primary completion
May 2028
Study completion May 2028
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Nov 17, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess how safe, effective, and tolerable ABBV-547 is in adult participants in the United States and Japan. There will be 2 parts to this study. In Part 1, participants are placed in one of 7 groups where they will receive ABBV-547 at different doses or placebo. There is a 1 in 4 chance participants will receive placebo. In Part 2, participants are placed in one of 4 groups where they will receive ABBV-547 at different doses or placebo. There is a 1 in 7 chance participants will receive placebo. Group 11 is the only group that will receive multiple doses. Approximately 142 adult participants will be enrolled at approximately 21 sites in the United States and Japan. Participants will be administered one dose or multiple doses of ABBV-547 or placebo. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Conditions
- Healthy Volunteer
- Psoriasis
Interventions
ABBV-547Drug
Parental Administration
ABBV-547 PlaceboDrug
Parental Administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Adverse Events (AEs)Time frame: Up to Approximately Day 365
Locations
20 sites in 2 countries. Site status is shown where the registry gives one.
Total Dermatology /ID# 279798
Birmingham, Alabama
Dermatology Trial Associates /ID# 279984
Bryant, Arkansas
CenExel Act- Anaheim Clinical Trials /ID# 279612
Anaheim, California
Dermatology Research Associates - Los Angeles /ID# 279383
Los Angeles, California
Integrative Skin Science and Research - Location 2 /ID# 279386
Sacramento, California
Wellness Clinical Research - Miami Lakes /ID# 279803
Miami Lakes, Florida
Advanced Clinical Research Institute - Tampa /ID# 279342
Tampa, Florida
Acpru /Id# 278638
Grayslake, Illinois
MetroBoston Clinical Partners /ID# 279992
Boston, Massachusetts
Minnesota Clinical Study Center /ID# 279987
New Brighton, Minnesota
MediSearch Clinical Trials /ID# 279416
Saint Joseph, Missouri
Skin Specialists /ID# 279531
Omaha, Nebraska
The Skin Center Dermatology Group. /ID# 279983
New City, New York
Equity Medical, LLC - Bronx /ID# 279808
The Bronx, New York
Oregon Dermatology and Research Center /ID# 279391
Portland, Oregon
Health Concepts /ID# 279529
Rapid City, South Dakota
Center for Clinical Studies - Houston - Binz Street /ID# 279419
Houston, Texas
Austin Institute for Clinical Research - Pflugerville /ID# 279387
Pflugerville, Texas
Fukuoka University Hospital /ID# 279530
Fukuoka, Japan
University of the Ryukyus Hospital /ID# 279918
Ginowan-shi, Okinawa, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.